Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This project is a phase Ib clinical trial study evaluating the efficacy and safety of TQB2618
injection combined with TQB2450 injection in patients with advanced solid tumors, the trial
plan to enroll 127 subjects, the trial design is a phase I.b dose exploration and cohort
expansion clinical study, aiming to evaluate the safety and efficacy of TQB2618 injection
combined with TQB2450 injection in patients with advanced malignant solid tumors, and to
evaluate TQB2618 injection, Pharmacokinetic characteristics, receptor occupancy and
immunogenicity characteristics of TQB2450 injection; Biomarker studies related to the
mechanism of action, safety and/or pathological mechanism of efficacy have dose-limiting
toxicity (DLT) in Phase I, recommended dose in Phase II (RP2D), and objective response rate
(ORR) in Phase II as the primary endpoints.